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Prevalence of Parental Thrombophilic
Defects After Fetal Death and Relation to
Cause
Fleurisca J. Korteweg, MD, PhD, Jan Jaap H. M. Erwich, MD, PhD, Nienke Folkeringa, MD, PhD,
Albertus Timmer, MD, PhD, Nic J. G. M. Veeger, MSc, PhD, Joke M. Ravisé, Jozien P. Holm, MD, PhD,
and Jan van der Meer, MD, PhD†
OBJECTIVE: To estimate whether parental thrombo-
philic defects after fetal death, either acquired or inher-
ited, were more prevalent than in the normal population
and to estimate associations between these thrombo-
philic defects and different fetal death causes.
METHODS: In a multicenter, prospective cohort study of
750 fetal deaths, we tested couples for antithrombin,
protein C, total and free protein S, and von Willebrand
factor (vWF) plasma levels. Mothers’ values were com-
pared with reference values in gestational age-matched
healthy pregnant women, and fathers were compared
with healthy men. Prevalence of factor V Leiden, pro-
thrombin G20210A mutation, and lupus anticoagulant
were compared with the normal population. A panel
classified death cause.
RESULTS: More women with fetal death had decreased
antithrombin (16.8%, P<.001) and protein C (4.0%, P.03)
and increased vWF (15.5%, P<.001) plasma levels than
healthy pregnant women (2.5%). However, compared with
normal ranges in the nonpregnant population, we only
observed more women with increased vWF (12.4%,
P<.001). More fathers had decreased free protein S (6.3%,
P<.001) and elevated vWF (12.1%, P<.001) than healthy
men (2.5%). Prevalence of inherited thrombophilias was not
higher in couples with fetal death than in the population.
Neither inherited nor acquired maternal or paternal throm-
bophilic defects were associated with the main cause of
death. Of placental causes, abruption and infarction were
associated with acquired maternal defects.
CONCLUSION: Except for vWF and paternal free pro-
tein S, acquired and inherited thrombophilic defects
were not more prevalent after fetal death. Routine
thrombophilia testing after fetal death is not advised.
(Obstet Gynecol 2010;116:355–64)
LEVEL OF EVIDENCE: II
Approximately one in 200 pregnancies ends instillbirth as a result of different causes.1 Mater-
nally inherited thrombophilic defects are inconsis-
tently recognized as risk factors for pregnancy com-
plications such as preeclampsia, placental abruption,
growth restriction, and stillbirth,2,3 whereas paternal
thrombophilic factors can also be transferred to the fetus
and placenta.4 Many studies have addressed the associ-
ation between inherited thrombophilic deficiencies and
late fetal loss in families with inherited deficiencies,
whereas case–control and cohort studies have studied
women with fetal loss who were tested for thrombo-
philia after delivery. In reviews, a higher risk for fetal
loss was observed for antithrombin and protein S defi-
ciency, factor V Leiden, the prothrombin 20210A mu-
tation, and anticardiolipin antibodies.5–7
The pathophysiology of late fetal loss associated
with inherited thrombophilia is presumed to be pla-
cental thrombosis either in the maternal or fetal
circulation of the placenta leading to placental infarc-
tion and placental insufficiency.8 This hypothesis has
been difficult to prove as a result of the small numbers
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involved in previous studies, whereas placental insuf-
ficiency was often poorly defined and not related to
cause of death.9–12 Pregnancy is a hypercoagulable
state resulting from acquired thrombophilic defects
exposing women to a higher risk of thrombosis.13 In
combination with preexisting inherited thrombo-
philic defects, it may increase the risk of fetal death.
Little is known about the contribution of acquired
thrombophilic defects to the hypercoagulable state
and fetal death because women in previous studies
were only tested for thrombophilia several weeks
after delivery.
The objective of our study was to estimate
whether in a cohort of women with intrauterine fetal
death, thrombophilic defects, either acquired during
pregnancy or preexisting inherited, and inherited
defects in fathers were more prevalent than in the
normal population. Furthermore, we estimated the
association between these thrombophilic defects and
the various fetal death causes within our cohort.
MATERIALS AND METHODS
In 2002, we initiated a prospective intrauterine fetal
death cohort study in 50 Dutch secondary and tertiary
referral hospitals serving rural as well as urban pop-
ulations. Inclusion criteria were singleton intrauterine
fetal death diagnosed antepartum (heart beat stopped
before labor) after 20 weeks of gestation calculated
from the last menstrual period and confirmed by
ultrasonography. Terminations were excluded. The
study was approved by the review boards of all the
participating hospitals, and written informed consent
was obtained from participants. Data were collected
for each intrauterine fetal death, including medical
and obstetric history, maternal and fetal characteris-
tics, and pregnancy and delivery details. Our diagnos-
tic workup protocol was based on local protocols and
included maternal blood tests, including full blood
count, chemistry, and viral serology; coagulation tests
for couples performed centrally at the laboratory in
Groningen; fetal blood tests, including viral serology;
microbiologic cultures from the mother, fetus, and
placenta; autopsy; placental examination; and cyto-
genetic analysis.
In women with intrauterine fetal death, plasma
levels of antithrombin, protein C activity, total and
free protein S antigen, and von Willebrand factor
(vWF) were measured in samples collected on induc-
tion of labor. These plasma levels were compared
with plasma reference values in 110 healthy pregnant
women of comparable gestational age recruited from
our obstetrics department after informed consent was
obtained. Women were excluded if they had an
individual or family history of venous thromboembo-
lism, known thrombophilia, complications in past
pregnancies or the present one, or if they used
medication. Healthy pregnant women were tested at
four intervals of gestation: 12–16 weeks, 28–32
weeks, in an early stage of labor (greater than 34
weeks), and 5–7 weeks postpartum. Reference plasma
values were determined for all cases for gestational
age periods from 20–27 weeks, 27–34 weeks, and
greater than 34 weeks (in an early stage of labor).
Values at 20–27 weeks of gestation were obtained by
linear estimation from values at 12–16 weeks and
28–32 weeks for each individual. Plasma levels of
antithrombin, protein C activity, total protein S anti-
gen, and free protein S antigen in women with
intrauterine fetal death were defined as abnormal if
they were below 2.5% of the values in healthy preg-
nant women at comparable gestational age or above
97.5% for vWF. Use of these cutoff values is common
when determining reference values.
We also measured plasma levels of antithrombin,
protein C activity, total protein S antigen, free protein
S antigen, and vWF in the fathers and we determined
normal plasma ranges in 393 healthy men recruited as
blood donors in our hospital who had no (family)
history of venous or arterial thromboembolism. Ab-
normal plasma levels were defined as levels below the
lower limit of the normal ranges: antithrombin less
than 74 international units/dL; protein C activity less
than 64 international units/dL; total protein S antigen
less than 67 international units/dL; and free protein S
antigen less than 65 international units/dL. von Wil-
librand factor levels greater than 150 international
units/dL were increased. All these abnormal plasma
levels are referred to as “thrombophilic defects.”
Antithrombin (Chromogenix, Mo¨lndal, Sweden)
and protein C activity (Dade Behring, Marburg, Ger-
many) were measured by chromogenic substrate as-
says; total protein S antigen, free protein S antigen,
and vWF were measured by enzyme-linked immu-
nosorbent assay (DAKO, Glostrup, Denmark).
In men and women, inherited thrombophilias fac-
tor V Leiden and the prothrombin G20210A mutation
were determined by polymerase chain reactions. Lupus
anticoagulant was determined as previously described.14
Prevalence of these thrombophilias was compared with
prevalence in the normal population.
Autopsies and placental examinations (including
histology) were performed by surgical as well as
perinatal pathologists in the participating hospitals.
We urged pathologists to follow the study protocol,
which was based on the guidelines published by the
Royal College of Obstetricians and Gynecologists
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and the Royal College of Pathologists15 and the
College of American Pathologists.16,17 Fetal growth
percentiles for birth weight by gestational age at time
of diagnosis of intrauterine fetal death were calculated
according to Kloosterman’s growth charts.18 Small for
gestational age was defined as birth weight less than
the 10th percentile.
Cause of fetal death was classified by a multidisci-
plinary panel according to the Tulip classification,19
which covers six main causes: congenital anomaly,
placental pathology, prematurity or immaturity, infec-
tion, other (ie, maternal diseases, fetal hydrops), or
unknown. The cause was classified as unknown if other
causes had been excluded. Risk factors, such as smoking
and preeclampsia, were defined as contributing to
death.
Causes of deaths resulting from maternal and
fetal placental circulation pathology were 1) placental
abruption, a clinical diagnosis supported by placental
examination; 2) significant infarction in preterm
cases, any placental infarction, and in term cases,
extensive infarction (greater than 10%) of the placen-
tal area. Infarction as a cause was allocated if the
percentage of infarctions in the parenchyma in rela-
tion to the weight of the placenta was regarded likely
to cause death. In a term placenta of appropriate
weight, at least 30% infarctions was regarded plausi-
ble to cause death.20 This is in accordance with
others21; 3) fetal thrombotic vasculopathy, the pres-
ence of avascular villi (at least one focus of five or
more villi), thrombosis in a vessel of the chorionic
plate or stem villus, hemorrhagic endovasculitis, or
intramural fibrin in a vessel of the chorionic plate or
stem villus in the absence of umbilical cord blood
flow restriction22,23; and 4) maternal floor infarct or
massive perivillous fibrin deposition, extensive periv-








Venous thromboembolism (first degree) 4.9 8.5 .07
Known hereditary thrombophilia 1.5 4.2 .06
Personal history
Venous thromboembolism 0.9 4.9 .001
Known hereditary thrombophilia 0 2.0 .006
Previous IUFD 2.7 3.8 .50
Recurrent early fetal loss 6.3 5.6 .87
Age (y) median (range) 32 (18–46) 30 (18–46) .005
Ethnic origin
White* 88.4 86.1 .31




Nulliparous 49.7 56.9 .20
Primiparous 21.9 18.4
Multiparous 28.4 24.7
Hypertension-related disease† 11.0 25.8 .001
Diabetes-related disease‡ 4.1 3.4 .84
Smoking 23.3 25.9 .83
Anticoagulant thromboprophylaxis 1.6 4.5 .028
Current IUFD
Gestational age (wk) mean (SD) 34.4 (6.3) 28.4 (5.7) .001
Birth weight (g) median (range) 2,000 (40–4,630) 810 (12–4,425) .001
Small for gestational age§ 28.8 43.0 .001
Time lag diagnosis and birth (d) median (range) 2 (0–40) 2 (0–23) .27
IUFD, intrauterine fetal death; SD, standard deviation.
Coagulation tests were available in 714 (95.2%); results are given in percent unless otherwise indicated.
* Including Mediterranean groups.
† Hypertension-related disease (chronic hypertension; pregnancy-induced hypertension; preeclampsia; hemolysis, elevated liver
enzymes, low platelet syndrome; and superimposed conditions) based on recommendations by the International Society for the
Study of Hypertension in Pregnancy.
‡ Diabetes-related (type I diabetes and gestational diabetes).
§ According to Kloosterman’s growth charts,18 which start at 25 weeks of gestation.
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illous fibrin deposition, either predominantly basally
located or diffusely distributed in at least 30% of the
parenchyma.24
Other categories of placental pathology were
placental hypoplasia, an absolute too-low placenta
weight (less than the 10th percentile), a too-low
placenta or birth weight ratio, or both25 and other
placental pathology such as villus immaturity and
umbilical cord complications.
Sample size of our initial national intrauterine
fetal death study was based on the ability to identify
less frequent but clinically relevant causes of death (ie,
5% rather than formal hypothesis testing). To achieve
sufficient precision, we considered a lower boundary
of the 95% confidence interval (CI) of 3.5%. This
resulted in a sample size of 750 fetal deaths. Categor-
ical variables were expressed as counts and percent-
ages and continuous data as means with standard
deviation or median and ranges with exact 95% CIs
given when appropriate. Differences between groups
for categorical data were evaluated by the Fisher’s
exact test or 2 test. For continuous variables, we used
the Student’s t test or Mann-Whitney U test, depend-
ing on the normality of data. A two-tailed P.05 was
considered to indicate statistical significance. Statisti-
cal analyses were performed using SAS software 9
(SAS Institute Inc, Cary, NC).
RESULTS
From 2002 to 2006, we enrolled 750 couples. Coagula-
tion tests were available in 714 (95.2%) women and 664
(88.5%) men. Autopsies were performed in 525 (70.0%)
fetal deaths and placental examinations in 736 (98.1%).
The characteristics of men and women with at
least one thrombophilic defect (22.4% and 37.4%,
respectively) and those without such defects are
shown in Tables 1 and 2). A personal history of
venous thromboembolism (4.9%) and known throm-
bophilia (2.0%), hypertension-related disease (25.8%),
and anticoagulant thromboprophylaxis during preg-
nancy (4.5%) were observed more often in women
with a thrombophilic defect. In this subgroup, median
age at pregnancy, mean gestational age at delivery
(28.4 weeks compared with 34.4 weeks), and median
birth weight were lower, whereas it also contained
more small-for-gestational-age babies.
Compared with reference values in nonpregnant
women, the majority of women with intrauterine fetal
death and healthy pregnant women had a tendency to
higher antithrombin levels, no difference in protein C
activity levels, a tendency to lower total protein S
antigen, lower free protein S antigen, and higher vWF
levels (Fig. 1). Compared with healthy pregnant
women, women with intrauterine fetal death had
lower levels of antithrombin and higher levels of vWF
up to 34 weeks of gestation.
Regarding acquired thrombophilic defects during
pregnancy, women with intrauterine fetal death more
often had significantly decreased levels of antithrombin
(16.8%) and protein C antigen (4.0%) and increased
vWF levels (15.5%) compared with healthy pregnant
women (2.5%; Tables 3 and 4). Decreased free protein S
antigen levels were less common (0.9%). When com-
pared with plasma levels in the normal, nonpregnant
population, decreased levels of antithrombin (3.7%,
P.07) and protein C antigen (2.1%, P.62) were not
observed more often in contrast to increased vWF levels
(87.6%, P.001) that were still observed more often in
women with intrauterine fetal death. The prevalence of
preexisting inherited thrombophilias factor V Leiden








Venous thromboembolism (first degree) 4.4 6.9 .26
Known hereditary thrombophilia 0.9 2.3 .19
Personal history
Venous thromboembolism 0.4 0.7 .53
Known hereditary thrombophilia 0.2 0.8 .40
Age (y) median (range) 34 (18–61) 35 (19–60) .01
Current IUFD
Gestational age (wk) mean (SD) 31.6 (6.3) 31.7 (6.7) .74
Birth weight (g) median (range) 1,485 (12–4,560) 1,395 (51–4,630) .98
Small for gestational age* 33.5 35.3 .74
IUFD, intrauterine fetal death; SD, standard deviation.
Coagulation tests were available in 664 (88.5%) men; results are given in percent unless otherwise indicated.
* According to Kloosterman’s growth charts,18 which start at 25 weeks of gestation.
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and prothrombin G20210A mutation in women with
intrauterine fetal death was comparable to the normal
population, whereas lupus anticoagulant (1.4%) was
observed less frequently than expected. Men in the
intrauterine fetal death group more often had decreased
free protein S antigen plasma levels (6.3%) and elevated
vWF levels (12.1%) compared with healthy men (2.5%).
Causes of death were placental pathology
(64.9%), congenital anomaly (5.3%), infection (1.9%),
other (4.8%), or unknown (23.1%: 15.9% despite
thorough investigation and 7.2% resulting from insuf-
ficient information). Table 5 presents thrombophilic
defects found in women with intrauterine fetal death
(n750) and their partners in relation to cause of
death. A thrombophilic defect was seen in 39.1% of
women with a placental cause compared with 34.1%
with a nonplacental cause. Overall, in both men and
women, none of the separate thrombophilic defects
were associated with placental compared with non-










































































































































































P < .001 P < .001 P = .57 P < .001 P = .002 P = .14
P = .004 P < .001 P < .001 P = .64 P < .001 P = .33
P < .001 P < .001 P = .29































Fig. 1. Plasma levels of natural anticoagulant proteins (antithrombin, protein C, total protein S, free protein S) and von
Willebrand factor according to gestational age (20–27 weeks, 27–34 weeks, and 34 weeks or more) in women with
intrauterine fetal death (IUFD), healthy pregnant women (Pregnant women), and male partners of women with IUFD (Men)
compared with reference values in the normal nonpregnant population (dotted line). P values indicate comparison between
women with IUFD compared with healthy pregnant women. A. Antithrombin. B. Protein C. C. Total protein S. D. Free
protein S. E. von Willebrand factor.
Korteweg. Thrombophilia Testing After Fetal Death. Obstet Gynecol 2010.
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antigen plasma levels were more often associated with
nonplacental causes, and elevated maternal vWF
levels were associated with “other cause of death.” In
addition, when we considered the 267 women with a
thrombophilic defect, 182 (68%) had an intrauterine
fetal death as a result of a placental cause (39.1% of
the 465 women with a placental cause). This was
comparable to the group of women without thrombo-
philic defects (283 of 447 [63%], P.20). Of the 149
men with a thrombophilic defect, 94 (63%) were in
the intrauterine fetal death group with placental
causes (21.7% of 434 men overall with a placental
cause), which is comparable to 340 of 515 men (66%,
P.56) without a defect. No association with placental
causes was observed in couples in which there was
both a maternal and a paternal thrombophilic defect
(32 of 53 [60%] compared with 199 of 317 [63%],
P.19) compared with couples without a defect.
Analysis of placental causes of death showed that
death was the result of infarction in 99 of 182 (54%)
and abruption in 30 of 182 (16%) women with a
thrombophilic defect (Table 6). Compared with all
the different placental causes, abruption was more
frequently associated with decreased levels of anti-
thrombin (40.8%, P.001), protein C activity (20.4%,
P.001), and total protein S antigen (10.2%, P.001)
and increased vWF levels (18.4%, P.03); infarction
was associated with decreased antithrombin (26.1%,
P.001) and elevated vWF (28.4%, P.001) levels
and lupus anticoagulant (2.4%, P.04) and maternal
floor infarct and massive perivillous fibrin deposition
with elevated vWF (28.6%, P.001). Abruption was
seen significantly more often in women with abnor-
mal plasma levels of antithrombin, protein C activity,
and total protein S antigen compared with infarction.
Overall, of placental causes, abruption and infarction
were most frequently observed in women with throm-
bophilic defects (P.001).
DISCUSSION
Our intrauterine fetal death cohort study was primar-
ily set up to evaluate valuable diagnostics to deter-
mine cause of fetal death. We addressed the contri-
bution of preexisting inherited as well as acquired
thrombophilic defects during pregnancy to fetal
death. Thrombophilia testing was therefore per-
formed at induction of labor and protein levels in
women with fetal death were compared with healthy
pregnant women of comparable gestational age. We
defined protein levels as potential risk factors for
thrombosis in pregnancy (ie, as thrombophilic de-
fects) when they were less than the 2.5th percentile in
healthy pregnant women for antithrombin, protein C
activity, and protein S antigen and greater than the












(No. Tested CI) P
Factor V Leiden 5% 6.7 (689 4.9–8.8) .06 5% 4.2 (642 2.8–6.1) .41
Heterozygous 6.4 4.0
Homozygous 0.3 0.2
Prothrombin G20210A 3% 3.0 (691 1.9–4.6) 1.0 3% 0.9 (642 0.3–2.0) .001
Heterozygous 3.0 0.9
Homozygous — —
Lupus anticoagulant 3% 1.4 (646 0.6–2.6) .01 3% 0 (105 0–3.5) .08
IUFD, intrauterine fetal death; CI, confidence interval.













(No. Tested CI) P
Antithrombin 2 2.5 16.8 (702 14.1–19.8) .001 2.5 0.3 (655 0.04–1.1) .001
Protein C 2 2.5 4.0 (708 2.6–5.7) .03 2.5 0.6 (661 0.2–1.5) .001
Total protein S 2 2.5 3.0 (707 1.9–4.5) .48 2.5 0.5 (659 0.1–1.3) .001
Free protein S 2† 2.5 0.9 (699 0.3–1.9) .003 2.5 6.3 (656 4.5–8.4) .001
vWF 1 2.5 15.5 (702 12.9–18.4) .001 2.5 12.1 (659 9.7–14.9) .001
IUFD, intrauterine fetal death; CI, confidence interval; vWF, von Willebrand factor.
* Reference values.
† Free protein S2 but normal total protein S.
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97.5th percentile for vWF. Testing for thrombophilia
after fetal death may be useful in clinical practice if
the results can be used to prevent recurrent fetal loss.
Our data provide no support for routine testing of
inherited or acquired thrombophilic defects after fetal
death, although acquired defects during pregnancy
may play a role in deaths caused by abruption or
infarction.
Overall, in women with fetal death, levels of
antithrombin and protein C antigen remained within
the normal ranges for nonpregnant women. These
levels are not related to a greater risk for thrombosis
in nonpregnant women, but cutoff levels for fetal loss
in pregnant women may differ. On the other hand,
these proteins may contribute to fetal loss through
mechanisms other than their anticoagulant properties,
for example, cell protection, inhibition of apoptosis of
trophoblast cells, and antiinflammatory effects.26 This
assumption was supported by our finding that intra-
uterine fetal death was diagnosed at earlier gestational
age and with more small-for-gestational-age fetuses in
women with these thrombophilic defects. However,
the higher rate of hypertension-related disease in this
group could also account for this with the thrombo-
philia being an epiphenomenon. Decreased levels of
protein S antigen and increased levels of vWF in most
healthy pregnant women, compared with reference
values in nonpregnant women, also suggested differ-
ent cutoff levels in pregnancy.
Significantly increased maternal vWF plasma lev-
els were observed in our intrauterine fetal death
group compared with healthy pregnant women in
which vWF levels increase during normal pregna-
ncy,13 but it is unknown when these levels become
pathologic. von Willibrand factor activity was found
to be higher in women with early miscarriage than in


















Women 18.5 (459) 13.9 (36) 21.4 (14) 18.8 (32) 11.8 (161) 13.6 (243) .11
Men 0.5 (428) 0 (36) 0 (11) 0 (32) 0 (148) 0 (227) .55
Protein C 2
Women 4.1 (462) 0 (38) 21.4 (14) 3.1 (32) 3.1 (162) 3.7 (246) .84
Men 0.5 (432) 0 (36) 0 (12) 0 (32) 1.3 (149) 0.9 (229) .61
Total protein S 2
Women 2.0 (461) 2.6 (38) 7.1 (14) 3.1 (32) 5.6 (162) 4.9 (246) .04
Men 0.2 (430) 0 (36) 0 (12) 0 (32) 1.3 (149) 0.9 (229) .28
Free protein S 2†
Women 0.9 (456) 0 (38) 0 (14) 0 (32) 1.3 (159) 0.8 (243) .99
Men 4.9 (430) 5.9 (34) 8.3 (12) 12.5 (32) 8.8 (148) 8.9 (226) .06
vWF 1
Women 17.1 (457) 7.9 (38) 14.3 (14) 34.4 (32) 9.3 (161) 12.7 (245) .13
Men 12.6 (429) 11.1 (36) 25.0 (12) 9.4 (32) 10.7 (150) 11.3 (230) .71
Factor V Leiden
Women 7.6 (447) 0 (37) 21.4 (14) 3.1 (33) 5.1 (158) 5.0 (242) .20
Men 4.5 (419) 5.7 (35) 0 (12) 3.1 (32) 2.8 (144) 3.1 (223) .41
Prothrombin G20210A
Women 3.4 (448) 0 (37) 7.1 (14) 0 (33) 3.1 (159) 2.5 (243) .65
Men 1.0 (419) 0 (37) 0 (12) 0 (32) 1.4 (144) 0.9 (223) .99
Lupus anticoagulant
Women 1.0 (422) 3.0 (33) 7.1 (14) 6.7 (30) 0.7 (147) 2.2 (224) .29
Men NA
Any defect
Women 39.1 (465) 21.1 (38) 64.3 (14) 51.5 (33) 31.1 (164) 34.1 (249) .20
Men 21.7 (434) 22.2 (36) 33.3 (12) 25.0 (32) 23.3 (150) 23.9 (230) .56
Couples 7.4 (432) 5.6 (36) 16.7 (12) 12.5 (32) 8.7 (149) 9.1 (229) .19
vWF, von Willebrand factor; NA, not applicable.
Percentages (no. tested) are given.
* P value for comparison of placental versus nonplacental causes.
† Free protein S2 but normal total protein S.
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control subjects.27 We speculated that our results
could be related to non-O blood type28 or an acute
phase response; non-O blood type was indeed asso-
ciated with higher vWF levels, whereas C-reactive
protein and fibrinogen were not (data not shown).
Abnormal paternal plasma levels of free protein S
antigen and vWF were observed in the intrauterine
fetal death group. Others reported no difference in
fetal mortality in women with partners with and
without inherited thrombophilia.29 In contrast, a dou-
bled prevalence (60%) of numerous thrombophilic
defects in partners of women with a history of peri-
natal mortality compared with control participants
(30%) was reported.30
Overall, factor V Leiden, prothrombin G20210A
mutation, and lupus anticoagulant were not associated
with fetal death. This is in contrast with earlier studies
that reported relative risks for late fetal loss of 2.1–3.3
for maternal factor V Leiden, 2.3–3.0 for maternal
prothrombinG20210Amutation, and 2.4 for maternal
lupus anticoagulant.6,7,31 Variation in population char-
acteristics could explain these differences.
Trophoblast invasion of the maternal uterine
circulation, spiral artery remodeling, and mainte-
nance of blood fluidity in the intervillous space re-
quire a balance between prothrombotic and anti-
thrombotic forces. Most deaths in our study were
caused by placental pathology. Overall for main
cause of death, none of the maternal and paternal
thrombophilic defects were related to a placental
cause nor for couples with double thrombophilic
defects. However, analysis of the various placental
causes of fetal death showed that thrombophilic de-
fects were associated with placental abruption and
infarction. Abruption was associated with decreased
levels of antithrombin, protein C activity, and total
protein S antigen and increased vWF levels; infarc-
tion with decreased antithrombin levels; increased
vWF levels; and lupus anticoagulant. Furthermore,
both pathologies were associated with combined
thrombophilic defects and thrombophilic defects in
fathers (decreased free protein S antigen, increased
vWF levels). Because placentas were examined by
different surgical as well as perinatal pathologists, we
must presume that there is interobserver variation
resulting in underestimation of placental pathologies
that are relatively difficult to establish. Our results
suggest that acquired thrombophilic defects may play
a role in deaths caused by abruption or infarction,
which represent one third of fetal deaths.
Measuring protein levels at the start of induction
in women with fetal death might have influenced our
results, because these were compared with healthy
pregnant women at comparable gestational age. Such
an effect seems less likely after comparing the results
in the various subgroups. The median time between
diagnosis of intrauterine fetal death and birth was 2
days, which makes it unlikely that dead fetus syn-
drome played a role.32 Placental abruption might be
the cause rather than the result of associated throm-
bophilic defects resulting from disseminated intravas-
cular coagulation. Similarly, hypertension-related dis-
ease may cause changes in protein levels as a result of
impaired liver function. To address possible con-




















Antithrombin 2 40.8 (49) 26.1 (184) 0 (2) 14.3 (7) 7.1 (28) 9.3 (86) 5.8 (103) .001
Protein C 2 20.4 (49) 3.3 (184) 0 (2) 0 (7) 0 (30) 2.3 (87) 1.0 (103) .001
Total protein S 2 10.2 (49) 1.7 (184) 0 (2) 0 (7) 0 (30) 1.2 (87) 0 (102) .002
Free protein S 2‡ 4.1 (49) 0.6 (183) 0 (2) 0 (7) 0 (29) 0 (87) 1.0 (99) .31
vWF 1 18.4 (49) 28.4 (183) 0 (2) 28.6 (7) 10.7 (28) 12.8 (86) 1.0 (102) .001
Factor V Leiden 4.2 (48) 8.0 (176) 0 (2) 0 (7) 6.7 (28) 3.6 (83) 12.9 (101) .28
Prothrombin G20210A 6.3 (48) 3.4 (177) 0 (2) 0 (7) 0 (30) 3.6 (83) 3.0 (101) .85
Lupus anticoagulant 0 (48) 2.4 (167) 0 (1) 0 (6) 0 (26) 0 (79) 0 (95) .41
Any defect women 61.2 (49) 52.9 (187) 0 (2) 42.9 (7) 23.3 (30) 25.3 (87) 20.4 (103) .001
Couples 15.2 (46) 9.8 (173) 0 (2) 0 (7) 0 (29) 5.1 (79) 4.2 (96) .008
FTV, fetal thrombotic vasculopathy; MFI, maternal floor infarct; MPFD, massive perivillous fibrin deposition; vWF, von Willebrand
factor.
Percentages (no. tested) are given.
* Combination groups 1 to 4: a combination of one of the following causes of death: abruption, infarction, FTV, and MFI/MPFD.
† P value indicates differences between all subgroups.
‡ Free protein S2 but normal total protein S.
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founding factors, we performed two extra subgroup
analyses. First, we excluded women who might have
had disseminated intravascular coagulation as a result
of abruption and, second, women with hypertension-
related disease. The results were similar to our overall
analyses, indicating limited, if any, confounding (data
not shown).
The need for routine testing of thrombophilic
defects after fetal death is not supported by our
results, except in women with a family history of
hereditary thrombophilia or a personal history of
venous thromboembolism and intrauterine fetal
death, in whom testing could help prevent further
maternal venous thromboembolisms.5 Testing of
women with a fetal death caused by abruption or
infarction can be considered. However, thrombo-
philia screening should only be performed in cases in
which proper management can be offered. As long as
there are no randomized controlled trials proving the
benefits of anticoagulant therapy in cases with known
thrombophilic factors in relation to late fetal loss, we
must be reserved about implementing a potentially
harmful intervention in pregnant women. Testing for
abnormal levels of antithrombin, protein C activity,
total protein S antigen, or vWF may yield predictors
for a subgroup at risk for fetal death caused by
abruption or infarction.
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